Condition: Breast Cancer · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer: A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer
This description comes directly from the study's public registry record.
Thomas Grinda, MD · +33 1 42 11 42 11 · thomas.grinda@gustaveroussy.fr
Chloé Serhal, PhD · +33 1 42 11 42 11 · chloe.serhal@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Gustave Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06508216